Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Feb;27(2):246–251. doi: 10.1128/aac.27.2.246

Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.

J R Rodríguez, C H Ramírez-Ronda, M Nevárez
PMCID: PMC176247  PMID: 4039118

Abstract

A total of 80 patients were randomized to receive either aztreonam or tobramycin for the treatment of lower respiratory tract infections caused by gram-negative bacilli; all these patients received clindamycin concomitantly. A total of 53 patients were randomized to receive aztreonam-clindamycin; of these, 46 were clinically evaluable and 39 were bacteriologically evaluable. Of the 46 clinically evaluable patients, 41 were considered cured, 3 failed to be cured, and 2 died during the study period of unrelated causes. Of the 39 bacteriologically evaluable patients, 36 were considered cured, and 3 failed to be cured. There were 26 clinically evaluable patients in the group randomized to receive tobramycin-clindamycin. Of them, 22 patients were considered cured, 3 failed to be cured, and 1 died of unrelated causes during the study period. There were 18 bacteriologically evaluable patients in the tobramycin-clindamycin group; 17 were cured, and 1 failed to be cured. The most common pathogens isolated from the patients were Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. All of the isolated organisms were susceptible to both tested antibiotics, except for a strain of Pseudomonas cepacia resistant to both tested antimicrobial agents and a strain of Enterobacter aerogenes and one of P. aeruginosa that were resistant to aztreonam. Very few adverse reactions related to the antibiotics were seen. These effects, when present, were transient and comparable in both studied groups, except for renal-function tests, which were altered in 7.7% of the patients randomized to receive tobramycin-clindamycin and in none of the patients randomized to receive aztreonam-clindamycin. Aztreonam-clindamycin is safe and effective for the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli when the organisms are susceptible.

Full text

PDF
246

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Breuer H., Cimarusti C. M., Denzel T., Koster W. H., Slusarchyk W. A., Treuner U. D. Monobactams--structure-activity relationships leading to SQ 26,776. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):21–28. doi: 10.1093/jac/8.suppl_e.21. [DOI] [PubMed] [Google Scholar]
  2. Fainstein V., Weaver S., Bodey G. P. Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother. 1982 Feb;21(2):294–298. doi: 10.1128/aac.21.2.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fuxench-López Z., Ramírez-Ronda C. H. Pharyngeal flora in ambulatory alcoholic patients: prevalence of gram-negative bacilli. Arch Intern Med. 1978 Dec;138(12):1815–1816. doi: 10.1001/archinte.1978.03630370033017. [DOI] [PubMed] [Google Scholar]
  4. Geckler R. W., Gremillion D. H., McAllister C. K., Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977 Oct;6(4):396–399. doi: 10.1128/jcm.6.4.396-399.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gross P. A., Neu H. C., Aswapokee P., Van Antwerpen C., Aswapokee N. Deaths from nosocomial infections: experience in a university hospital and a community hospital. Am J Med. 1980 Feb;68(2):219–223. doi: 10.1016/0002-9343(80)90357-5. [DOI] [PubMed] [Google Scholar]
  6. Hawley H. B., Lewis R. M., Swartz D. R., Gump D. W. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis. Curr Ther Res Clin Exp. 1974 May;16(5):414–423. [PubMed] [Google Scholar]
  7. Johanson W. G., Jr, Higuchi J. H., Chaudhuri T. R., Woods D. E. Bacterial adherence to epithelial cells in bacillary colonization of the respiratory tract. Am Rev Respir Dis. 1980 Jan;121(1):55–63. doi: 10.1164/arrd.1980.121.1.55. [DOI] [PubMed] [Google Scholar]
  8. Johanson W. G., Pierce A. K., Sanford J. P. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of gram-negative bacilli. N Engl J Med. 1969 Nov 20;281(21):1137–1140. doi: 10.1056/NEJM196911202812101. [DOI] [PubMed] [Google Scholar]
  9. LaForce F. M. Hospital-acquired gram-negative rod pneumonias: an overview. Am J Med. 1981 Mar;70(3):664–669. doi: 10.1016/0002-9343(81)90593-3. [DOI] [PubMed] [Google Scholar]
  10. Laforce F. M., Hopkins J., Trow R., Wang W. L. Human oral defenses against gram-negative rods. Am Rev Respir Dis. 1976 Nov;114(5):929–935. doi: 10.1164/arrd.1976.114.5.929. [DOI] [PubMed] [Google Scholar]
  11. Livermore D. M., Williams J. D. In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):29–37. doi: 10.1093/jac/8.suppl_e.29. [DOI] [PubMed] [Google Scholar]
  12. Mackowiak P. A., Martin R. M., Smith J. W. The role of bacterial interference in the increased prevalence of oropharyngeal gram-negative bacilli among alcoholics and diabetics. Am Rev Respir Dis. 1979 Sep;120(3):589–593. doi: 10.1164/arrd.1979.120.3.589. [DOI] [PubMed] [Google Scholar]
  13. Murray P. R., Washington J. A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975 Jun;50(6):339–344. [PubMed] [Google Scholar]
  14. Pierce A. K., Sanford J. P. Aerobic gram-negative bacillary pneumonias. Am Rev Respir Dis. 1974 Nov;110(5):647–658. doi: 10.1164/arrd.1974.110.5.647. [DOI] [PubMed] [Google Scholar]
  15. Ramirez-Ronda C. H., Fuxench-López Z., Nevárez M. Increased pharyngeal bacterial colonization during viral illness. Arch Intern Med. 1981 Nov;141(12):1599–1603. doi: 10.1001/archinte.141.12.1599. [DOI] [PubMed] [Google Scholar]
  16. Ramírez-Ronda C. H., Gutiérrez J., Bermúdez R. H. Comparative effectiveness, safety and tolerance of mezlocillin and ticarcillin: a prospective randomized trail. J Antimicrob Chemother. 1982 Jan;9 (Suppl A):125–129. doi: 10.1093/jac/9.suppl_a.125. [DOI] [PubMed] [Google Scholar]
  17. Rodriguez J., Vazquez G. J., Bermudez R. H., Luina A., Ronda C. H. A randomized clinical trial of ceftizoxime and cefamandole in the treatment of serious lower respiratory tract infections. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):209–213. doi: 10.1093/jac/10.suppl_c.209. [DOI] [PubMed] [Google Scholar]
  18. Schentag J. J., Plaut M. E., Cerra F. B. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother. 1981 May;19(5):859–866. doi: 10.1128/aac.19.5.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Stevens R. M., Teres D., Skillman J. J., Feingold D. S. Pneumonia in an intensive care unit. A 30-month experience. Arch Intern Med. 1974 Jul;134(1):106–111. [PubMed] [Google Scholar]
  20. Sugarman B. Zinc and infection. Rev Infect Dis. 1983 Jan-Feb;5(1):137–147. doi: 10.1093/clinids/5.1.137. [DOI] [PubMed] [Google Scholar]
  21. Thadepalli H., Rao B. Clinical evaluation of mezlocillin. Antimicrob Agents Chemother. 1979 Nov;16(5):605–610. doi: 10.1128/aac.16.5.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thorsteinsson S. B., Musher D. M., Fagan T. The diagnostic value of sputum culture in acute pneumonia. JAMA. 1975 Aug 25;233(8):894–895. [PubMed] [Google Scholar]
  23. Valenti W. M., Trudell R. G., Bentley D. W. Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med. 1978 May 18;298(20):1108–1111. doi: 10.1056/NEJM197805182982002. [DOI] [PubMed] [Google Scholar]
  24. Van Scoy R. E. Bacterial sputum cultures. A clinician's viewpoint. Mayo Clin Proc. 1977 Jan;52(1):39–41. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES